A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
Phase 2
Active, not recruiting
- Conditions
- Calcific Aortic Valve Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- REDNVIA Co., Ltd.
- Target Recruit Count
- 867
- Registration Number
- NCT05143177
- Locations
- 🇺🇸
Mayo Clinic, AZ, Scottsdale, Arizona, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath